Nuveen Asset Management LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Nuveen Asset Management LLC cut its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 71.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 314,275 shares of the biotechnology company's stock after selling 792,421 shares during the quarter. Nuveen Asset Management LLC owned about 0.21% of Heron Therapeutics worth $481,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Nicolet Advisory Services LLC purchased a new position in shares of Heron Therapeutics during the fourth quarter valued at about $25,000. Argent Advisors Inc. bought a new stake in Heron Therapeutics during the 4th quarter valued at approximately $31,000. Focus Partners Wealth bought a new stake in Heron Therapeutics during the 4th quarter valued at approximately $31,000. Cutter & CO Brokerage Inc. grew its holdings in shares of Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 13,600 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Heron Therapeutics by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 8,684 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Price Performance

NASDAQ:HRTX traded up $0.10 during mid-day trading on Friday, hitting $2.10. 1,707,789 shares of the company's stock were exchanged, compared to its average volume of 2,245,708. The company has a market cap of $320.38 million, a PE ratio of -11.67 and a beta of 1.15. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The business has a fifty day moving average price of $2.02 and a 200 day moving average price of $1.87.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. On average, equities analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday. Needham & Company LLC reissued a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, April 11th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.